BRIEF-Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data

Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics

Pasithea Therapeutics Corp.

KTTA

0.00

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics

KTTAW

0.00

June 30 (Reuters) - Pasithea Therapeutics Corp KTTA.O:

  • ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRAF-PRETREATED PATIENTS, PLUS PROTOCOL EXPANSION

  • PAS-4 SHOWS FAVORABLE SAFETY PROFILE WITH ONLY GRADE 1 OR 2 ADVERSE EVENTS

  • PROTOCOL AMENDMENT EXTENDS DOSE ESCALATION UP TO 52MG FOR PAS-4

  • INITIATES PILOT FOOD EFFECT STUDY FOR PAS-4 PHARMACOKINETICS

Source text: ID:nGNX31bmmG

Further company coverage: KTTA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.